Evotec partner Celmatix achieves milestone for PCOS drug programme

  • Evotec partner Celmatix, a biotechnology company focused on ovarian biology, today announced that a third milestone has been achieved in its five-year, multi-target alliance with Evotec. The milestone was triggered by Evotec and Bayer AG advancing a drug programme, centered around a novel Celmatix-identified drug target, into hit-identification. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-partner-celmatix-achieves-milestone-for-pcos-drug-programme-6134

    Du magst vielleicht auch